pharmafocus_sept_2016_cover

The September issue of Pharmafocus is now live!

pharmafile | August 31, 2016 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bristol-Myer's Squibb, Bristol-Myers Squibb, CDF, Cancer Drugs Fund, Cloud Computing, Pharmafocus, Pharmafocus new issue, brexit, clinical trial transparaency, opdivo 

The latest edition of Pharmafocus is available online now. In this issue, we explore the future of the clinical trial by looking at two of the most pressing issues in this field at the moment: transparency and cloud computing. Both offer opportunities as well as potential pitfalls. Our exclusive features look at how both could be a shot in the arm for the industry.

The big story this week is the shock news that Bristol-Myers Squibb’s Opdivo had failed to meet its endpoint in a Phase III trial.  Our front page story looks at where BMS goes from here, while our in-depth look at the newly-reformed Cancer Drugs Fund examines the criticism it has attracted and how it can win over a doubting pharma industry going forward.

And in our special in-depth feature on Brexit, we focus on the impact that Britain’s exit from the EU will have on the life sciences industry in general and what all pharma companies, big and small, will need to remain aware of in the post-EU landscape.

Related Content

NICE approves first treatment for obstructive HCM for NHS use

The National Institute for Health and Care Excellence (NICE) has announced that it has approved …

img_4190-e1376666350337-web

New targeted lung cancer treatment coming to UK under MHRA scheme

The MHRA has issued an Early Access to Medicines Scheme (EAMS) positive scientific opinion for …

img_4190-e1376666350337-web

Sickle cell therapy granted innovation passport by MHRA

Bluebird bio has been granted an innovation passport, under the new UK approval process, for …

Latest content